石药集团(01093.HK)选择性5-HT2A受体激动剂获准在美国临床试验

Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials for its Class 1 chemical drug, a selective 5-HT2A receptor agonist (SYH2056 tablets) [1] Group 1 - The product has also been approved by the National Medical Products Administration (NMPA) in China to conduct clinical trials starting from November 2025 [1]